SCHEMBL23168750

SCHEMBL23168750

Nc1cc(Cl)c(Oc2ccc(=O)n(Cc3ccccc3)n2)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ PDE4A P27815 1/20 0.43
▸ PDE4B Q07343 1/20 0.43
▸ PDE4C Q08493 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ PTGS2 P35354 2/20 0.43
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ LMNA P02545 3/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MGLL Q99685 1/20 0.40
▸ ABHD6 Q9BV23 1/20 0.40
▸ NPBWR1 P48145 1/20 0.39
▸ PTGDR2 Q9Y5Y4 1/20 0.39
▸ HTR2C P28335 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24822266 0.83 PTGS2 (0.40) ALDH1A1MAPTPTGS2SMN1; SMN2LMNA
SCHEMBL24819267 0.80 KMT2A (0.49) ALDH1A1MAPTKMT2AMEN1SMN1; SMN2
SCHEMBL23168742 0.77 NPC1 (0.41) ALDH1A1MAPTKDM4EHPGDPDE4A
SCHEMBL23152132 0.75 MAPT (0.38) ALDH1A1MAPTKDM4EPTGS2KMT2A
SCHEMBL23168840 0.75 TSHR (0.53) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL23168782 0.75 FAAH (0.41) MAPTMGLLNPBWR1
SCHEMBL24820993 0.73 MKNK1 (0.42) ALDH1A1MAPTKMT2AMEN1NPBWR1
SCHEMBL24820997 0.73 MAPT (0.38) MAPTNPBWR1
SCHEMBL24821005 0.72 MAPT (0.35) MAPT
SCHEMBL9472059 0.72 ALDH1A1 (0.56) METALDH1A1MAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617769-B2 Chemical compound as thyroid hormone beta receptor agonist and use thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2026-05-05 — — US disclosed
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-12-29 — — US disclosed
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-12-29 — — US disclosed
EP-4036090-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2022-08-03 — — EP disclosed
WO-2021057791-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF 广东东阳光药业有限公司 2021-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF THRB, TSHR, THRA MET 61/4885ALDH1A1 1134/4885MAPT 1873/4885
US-12617769-B2 Chemical compound as thyroid hormone beta receptor agonist and use thereof THRB, TSHR, THRA MET 58/4885ALDH1A1 1340/4885MAPT 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback